Hoba Therapeutics among companies selected by the European

Press release

Hoba Therapeutics, a biotechnology company developing novel disease modifying therapies for pain and hearing loss, has been selected by The European Commission’s European Innovation Council (EIC) as a start-up champion. Hoba will receive grant funding and qualifies for further equity investment from EIC Accelerator.

Torsten M. Madsen, CEO of Hoba Therapeutics, comments: “We are grateful to the European Innovation Council for selecting our project among the many applicants. The funding will allow us to accelerate development of our pipeline towards clinical testing.” The funding will support the development of HB-086 for the treatment of neuropathic pain and HB-097 for the treatment of hearing loss. “We are excited to have received this recognition of both our innovative
pipeline, the continued plans, and our team.”

Hoba has previously received grant support from The Danish Innovation Fund, through their Grand Solution and Innobooster programs.

“Our investors, Novo Holdings, The Danish Growth Fund, Borean Innovation, and The Danish Agency for Higher Education and Science have funded Hoba’s mission to develop novel therapeutics for the treatment of pain and hearing loss. They have been instrumental in taking Hoba to its current stage. We look forward to the discussions with the EIC Fund and to have them contribute to the future success of Hoba Therapeutics.”

Link to press release from EIC: EIC announces new wave of start-up champions (europa.eu)

For further information: Torsten M. Madsen, CEO: tmma@hobatherapeutics.com

Other press releases

Hoba Therapeutics Appoints Jean Combalbert as Chairperson of the Board ofDirectors.

Hoba Therapeutics, a Danish biotech company dedicated to developing novel therapeutic proteins for patients living ...

Hoba Therapeutics raises EUR 23 million in a Series A to advance new drug candidate against chronic neuropathic pain

Hoba Therapeutics, a Novo Holdings founded Danish biotech company dedicated to developing novel therapeutic ...

Eir Ventures invests in Hoba Therapeutics

Hoba Therapeutics, a biotech company developing novel therapeutic proteins for pain, hearing loss, and sensory ...